Entrada Therapeutics (TRDA) Stock
Small biotech developing cell delivery technology for drugs. Here's the price, business snapshot, and what's worth knowing about Entrada Therapeutics in October 2026.
Entrada Therapeutics, Inc. (ticker TRDA) is a biotechnology company developing technologies aimed at delivering large-molecule therapies into cells. The company's work focuses on enabling intracellular delivery of oligonucleotides, proteins and other biologics — a technical challenge that could broaden the applicability of nucleic‑acid and protein medicines. With a market capitalisation of $241.92M, Entrada's value drivers are likely to include pipeline progress, partnerships and any validation of its delivery platform. Investing in small‑cap biotechs carries higher risk: development timelines can be long, R&D spending is typically substantial, outcomes may be binary and equity dilution is common. This summary is for general educational purposes only and does not constitute financial advice. Consider company filings, cash runway, clinical or regulatory milestones and consult a regulated financial adviser to assess whether TRDA fits your risk profile and investment horizon.
Entrada Therapeutics (TRDA) Stock Forecast
Analyst price target, next 12 months
$20.83
+372.4% vs today's $4.41
Price range over the last 12 months
Close to its 12-month low
Analysts covering Entrada Therapeutics have a consensus 12-month target of $20.83, above the current price of $4.41.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Entrada Therapeutics stock, with a target price suggesting significant potential growth.
Financial Health
Entrada Therapeutics has moderate revenue and cash flow, indicating stable but unremarkable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
Why You’ll Want to Watch This Stock
Platform Potential
A delivery platform could expand which diseases are treatable and create licensing opportunities, though technical and clinical validation remain crucial.
Early-stage Programme
Progress in preclinical or early clinical programmes can be catalytic for valuation, but outcomes are uncertain and timelines can be lengthy.
Partnering & Licensing
Collaborations can de‑risk development and provide funding; however, deal terms, milestones and future financing needs are important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
